New Synthetic Routes toward CBB3001 and Their Derivatives

Title:

New Synthetic Routes toward CBB3001 and Their Derivatives

Tech ID:

2024-004

Status:

Active

Category:

Chemistry, Biochemistry, Pharmaceutical Development

Executive Statement:

Efficient synthetic methods for producing anti-cancer agents based on CBB3001 and its derivatives.

Description:

This technology introduces novel and optimized synthetic routes to create CBB3001 and its derivatives, compounds known for their potent anti-cancer properties. The new methods improve yield, reduce reaction steps, and enhance scalability, enabling more effective production of these therapeutic agents.

Key Advantages:

• Improved synthesis efficiency with higher yields
• Reduced complexity and number of reaction steps
• Scalable processes suitable for industrial production
• Enhanced purity and consistency of final compounds
• Facilitates rapid development of diverse derivatives

Problems Solved:

• Low yield and inefficiency in existing synthesis methods
• Complicated and time-consuming production processes
• Difficulty in scaling up production for commercial use
• Inconsistent quality of anti-cancer agents

Marketing Opportunity:

• Pharmaceutical manufacturing of anti-cancer drugs
• Research and development of new oncology therapeutics
• Biotech companies focusing on cancer treatment compounds
• Contract manufacturing organizations for drug synthesis

Inventors: 

• Jun Yong Kang 
• Jeffrey Ash 
• Citlally Lopez 

Intellectual Property: 

• U.S. Provisional Patent 63/644,458, filed 5/8/2024
• U.S. Patent Cooperation Treaty PCT/US2025/027996, filed 5/6/2025